克罗恩病肠系膜切除与保守局限切除的国际多中心随机对照试验研究方案
这项国际多中心随机对照试验计划纳入116例初次回结肠切除的克罗恩病患者,随机分为广泛肠系膜切除组(EME)或传统局限肠系膜切除组(LME)。主要终点为术后手术复发,次要终点包括术后内镜和临床复发及围手术期并发症。若EME能降低复发且不增加并发症,可能改变临床实践。
要点
- EME组按CME原则切除肠系膜但避开根部1 cm,LME组保留肠系膜(紧贴肠管或<3 cm)。
- 主要终点为术后手术复发,分析基于意向性治疗。
- 需评估EME是否降低复发且不增加围手术期并发症。
核心结论
- 若肠系膜切除能降低克罗恩病术后复发且不增加并发症,该试验可能改变手术实践。
研究设计与样本
- 国际多中心随机对照试验,计划随机化116例拟行初次回结肠切除的克罗恩病患者。
- 五个中心在三个国家招募患者,随机分为EME组或LME组。
关键数值与推荐
- EME组按CME原则切除肠系膜,但避开根部区域(距回结肠动静脉根部1 cm)。
- LME组保留肠系膜,即「紧贴肠管」或距肠管边缘<3 cm。
- 主要终点为术后手术复发,次要终点为术后内镜和临床复发及围手术期并发症。
- 主要结局分析基于意向性治疗。
临床怎么用
- 该试验结果可能为克罗恩病手术中肠系膜切除范围提供证据,指导降低术后复发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The structures of the mesentery including adipose tissue, nerves, and lymphatics play an important role in the pathogenesis and disease progression of Crohn's disease (CD). Conventional surgical resection for CD usually does not involve resecting the mesentery en bloc with the specimen. This contrasts with complete mesocolic excision (CME) in colorectal cancer, which involves radical resection of the mesentery. Preliminary evidence from smaller studies suggests that applying the principle of mesocolic excision to CD surgery may reduce the risk of postoperative recurrence. This randomized controlled trial is designed to test whether applying the principles of mesocolic excision to CD results in reduced postoperative recurrence. It also aims to evaluate intra- and postoperative morbidity between the two approaches. METHODS: This international, multicenter, randomized controlled trial will randomize patients (n = 116) scheduled to undergo primary ileocolic resection to either receive extensive mesenteric excision (EME) or conventional ileocolic resection with limited mesenteric excision (LME). Five sites will recruit patients in three countries. In the EME group, the mesentery is resected following CME, while avoiding the root region, i.e., 1 cm from the root of the ileocolic artery and vein. In the LME group, the mesentery is retained, i.e., "close shave" or < 3 cm from the border of bowel. The primary end point will be surgical recurrence after surgery. The secondary end points will be the postoperative endoscopic and clinical recurrence, and intra- and postoperative morbidity. Demographics, risk factors, laboratory investigations, endoscopy, postoperative prophylaxis and imaging examination will be assessed. Analysis of the primary outcome will be on an intention-to-treat basis. DISCUSSION: If mesocolic excision in CD reduces postoperative disease recurrence and does not increase morbidity, this trial has the potential to change practice and reduce recurrence of CD after surgical resection. TRIAL REGISTRATION: Clinical Trials.gov, ID: NCT03769922. Registered on February 27, 2019.
引用
- Li Y, Mohan H, Lan N, et al. Mesenteric excision surgery or conservative limited resection in Crohn's disease: study protocol for an international, multicenter, randomized controlled trial. Trials. 2020. PMID: 32085793. doi:10.1186/s13063-020-4105-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。